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Functional impairment remains one of the most challenging issues for treatment in schizophrenia. However, previous studies have
mainly focused on the negative impact of symptoms excluding variables that could positively impact functional outcome, such as
creativity, which is considered an adaptive capacity for real-life problem-solving. This study analyzed the predictive role of creativity
on functional outcome in 96 patients with schizophrenia through a mediational model, including sociodemographic, clinical,
neurocognitive, and social cognitive variables. Path analysis revealed that creativity significantly mediated the relationship between
neurocognition and functional outcome, and that creativity mediated between negative symptoms and functional outcome.
Additionally, neurocognition was directly associated with functional outcome and social functioning was associated with creativity.
The involvement of creativity in functional outcome could have relevant implications for the development of new interventions.
These findings open up a new field of research on additional personal resources as possible factors of functional outcome in
schizophrenia and other diseases.
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INTRODUCTION
In spite of advances in pharmacological and psychological
treatments, schizophrenia is still considered one of the most
disabling disorders in the world1. Patients with schizophrenia
experience difficulties in a variety of daily life functioning domains,
mainly in independent living, occupational functioning, and social
functioning2. This functional impairment not only affects the
patients’ quality of life, but also has indirect effects on their
relatives and caregivers3. Furthermore, this impairment leads to a
very high financial cost4. For all these reasons, it is necessary to
correctly identify the factors that hinder functional outcome in this
disease in order to establish better potential treatment targets.
Indeed, in the last two decades, there has been a burst of interest
in studying factors underlying functional impairment of people
with schizophrenia4. The main factors that have been proposed
are cognitive impairment and severity of clinical symptoms5–9.
Regarding clinical symptoms, both negative and positive
symptoms have been related to functional outcome1,10,11,
although the former seems to have a greater impact6,12–14.
Moreover, primary negative symptoms seem to contribute to
functional outcome after controlling for secondary negative
symptoms such as those related to medication10. Specifically,
motivational deficits have shown to be the most robust predictors
of functional outcome15. Another clinical factor that has also been
related to functional outcome is disorganization, which is closely
related to neurocognition1.
With respect to cognition, cognitive deficits in neurocognition
and social cognition seem to be a core feature of this disease16.
Numerous studies have shown that cognitive functioning is a
main predictor of functional outcome in schizophrenia1,6,8,9,17–20.
Interestingly, a meta-analysis carried out by Fett et al.21 found that
social cognition had a stronger involvement in functional outcome
than neurocognition. Furthermore, evidence from several studies
suggests that social cognition could act as a mediator between
neurocognition and functional outcome1,22–24. Additionally, clin-
ical symptoms, mainly negative symptoms, have also been
suggested to mediate between cognition and functional
outcome6,12,13.
Besides these clinical and cognitive factors, it has been
suggested that other kinds of personal resources could also be
important determinants of real-life functioning1,11. In particular,
creative capacity could be crucial for functional outcome in
schizophrenia25. Creativity consists of the capacity to produce
something original or novel and appropriate or useful for a task26.
Evidence from studies carried out in the general population
indicates that creativity is a key component for real-life problem-
solving27 and it is considered an essential resource for adaptation
and coping with daily life adversities in healthy people28,29. This
capacity increases the ability to perform everyday activities
through the application of creative problem-solving skills to daily
life problems30. Moreover, creativity applied to our daily life has
been shown to improve individuals’ physical and psychological
health as well as self-competency, life satisfaction, social life, civil
participation, and academic and job performance31–33. Regarding
creativity in schizophrenia, a recent meta-analysis indicates that
people with this disease show a worse creative performance than
the general population34. Nemoto et al.25 found higher creativity
to be related to better functional outcome in schizophrenia.
Specifically, these authors found that verbal creativity (measured
through an idea fluency test)35 was related to daily living and
community functioning and figural creativity (measured through a
design fluency test)35 was associated with interpersonal relations
and community functioning25. In this study, in addition to
creativity, negative symptoms and general psychopathology
predicted functional outcome, but not neurocognition25. In
another study, nonverbal creativity was related to different coping
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strategies within schizophrenia spectrum and bipolar disorder36.
Additionally, in a pilot study, a creativity intervention was shown
to improve negative symptoms, creativity, general psychopathol-
ogy, global functioning, and interpersonal relations37. Likewise,
research carried out among the elderly and people with bipolar
disorder have suggested that creativity may act as a compensa-
tory advantage for better daily functioning and well-being31,32.
Thus, evidence suggests that those patients with schizophrenia
who have better creative skills may possibly benefit from this
resource for better and more adaptive daily life functioning.
Although creativity has been defined as a complex multi-
dimensional construct, it is not a completely independent variable
in schizophrenia. Previous literature suggests that creativity is
closely related to neurocognition and social cognition in schizo-
phrenia38–42. Specifically, both social cognition and neurocogni-
tion have been shown to play a mediatory role in the relationship
between creativity and schizophrenia40. Additional evidence
comes from studies that have found the metacognitive ability
(which is related to creative thinking)43,44 to be associated with
functional outcome in schizophrenia45,46 as well as to mediate the
relationship between neurocognition and functional outcome in
this disease47. In addition to cognition, clinical symptoms,
specifically negative symptoms, have also been shown to predict
creativity39,41.
Altogether, the literature suggests that functional outcome in
schizophrenia may be explained not only by factors such as
clinical symptoms and cognitive impairment, but also by other
factors like creative ability. However, as far as the authors are
aware, to date no study has explored the predictive value of
creativity on functional outcome in this disease through a
mediational model including clinical symptoms, neurocognition,
and social cognition. Therefore, the aim of this study was to
analyze the contribution of creativity in functional outcome of
patients with schizophrenia through a mediational model analyz-
ing the interplay of clinical symptoms, neurocognition, social
cognition, and creativity when explaining their contribution to
functional outcome. Based on previous evidence, it was hypothe-
sized that creative capacity would be associated with functional
outcome, mediating the association between neurocognition,
social cognition, negative symptoms, and functional outcome in
schizophrenia.
RESULTS
The average performance scores on clinical, neurocognitive, social
cognitive, creativity, and functional outcome tests are shown in
Table 1. To check the association between sociodemographic data
and the rest of the variables of the study, correlation analyses
were performed (Table 2). Additionally, correlations between
neurocognitive individual domains, social cognitive domains,
creativity, and functional outcome are shown in Supplementary
Table 1. Several statistically significant associations were found.
Regarding sociodemographic variables, sex (being female) corre-
lated significantly and negatively with negative symptoms (rpb=
−0.261, p= 0.010) and excitement (rpb=−0.237, p= 0.020). Age
correlated significantly and negatively with neurocognition (r=
−0.386, p < 0.001) and social cognition (r=−0.334, p= 0.001),
and positively with duration of illness (r= 0.856, p < 0.001). Finally,
years of education correlated significantly and negatively with
disorganization (rs=−0.260, p= 0.010) and excitement (rs=
−0.221, p= 0.031), and positively with neurocognition (rs=
0.317, p= 0.002) and social cognition (rs= 0.254, p= 0.013).
Additionally, correlations between clinical characteristics, neu-
rocognition, social cognition, creativity, and functional outcome
were performed (Table 3). As can be seen, functional outcomes
correlated positively and significantly with neurocognition (r=
0.244, p= 0.017) and figural creativity (r= 0.270 p= 0.008).
Table 1. Descriptive data of clinical, neurocognitive, social cognitive,
creativity, and functional outcome measures.
M (SD)
Clinical characteristics
PANSS Positive 9.98 (4.22)
PANSS Disorganization 7.78 (2.67)
PANSS Excitement 7.92 (3.71)
PANSS Depression 6.37 (2.41)
BNSS 31.67 (14.14)
Neurocognition
M-WCST categories 3.24 (1.78)
M-WCST perseverative errors 7.41 (8.13)
Stroop Word 90.47 (18.94)
Stroop Color 57.13 (14.25)
Stroop Word-Color 33.47 (10.90)
Backward Digit Span 4.96 (1.51)
HVLT three learning trials 17.46 (4.81)
HVLT delayed recall 5.02 (2.45)
Symbol-Coding 45.98 (15.28)
Social cognition




Figural creativity 48.75 (19.56)
Figural strengths 2.47 (2.35)
Verbal creativity 17.73 (9.18)
Functional outcome
SFS (short version) 23.45 (5.01)
M=Mean, SD= Standard deviation, PANSS= Positive and Negative Syn-
drome Scale, BNSS= Brief Negative Symptom Scale, M-WCST=Modified
Wisconsin Card Sorting Test, HVLT= The Hopkins Verbal Learning Test, SAT-
MC-II= Social Attribution Task-Multiple Choice II; BLERT= Bell Lysaker
Emotion Recognition Test, SFS= Social Functioning Scale.
Table 2. Correlations between sociodemographic variables with









−0.011 0.856** −0.150 0.059
Negative
symptoms
−0.261* 0.012 −0.154 0.153
Positive symptoms −0.121 −0.101 −0.146 0.053
Disorganization −0.159 0.039 −0.260* 0.183
Excitement −0.237* −0.115 −0.221* 0.035
Depression −0.047 −0.074 0.038 0.135
Neurocognition 0.015 −0.386** 0.317* −0.037
Social cognition −0.058 −0.334** 0.254* −0.188
Figural creativity 0.122 −0.064 0.105 −0.133
Figural strengths −0.017 −0.141 0.127 −0.192
Verbal creativity 0.057 −0.032 0.167 −0.031
Functional
outcome
0.092 0.023 0.137 0.112
*p ≤ 0.05; **p ≤ 0.001.
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Mediational model explaining functional outcome
A model with path analysis was estimated based on previous
literature1,22,24,40 and including only paths between the predictors
and the mediating or outcome variables that had correlated
significantly in the previous analyses. Therefore, positive symp-
toms, excitement, depression, figural strengths, and verbal
creativity were not included in the model. Since sex, age, years
of education, and duration of illness correlated significantly with
several predictors, these were entered in the model. The fit of the
model was very good, SB χ2 (28, N= 96) = 32.162, Comparative Fit
Index (CFI)= 0.974, Non-Normed Fit Index (NNFI)= 0.959, and
Standard Residual Mean Square Root (SRMR)= 0.061.
As some of the associations were not statistically significant (the
paths from age, years of education and disorganization to social
cognition, and the covariance between disorganization and
negative symptoms), a new model was estimated only with
significant paths. The final model obtained is presented in Fig. 1.
As can be seen, on the one hand, neurocognition was positively
associated with figural creativity and social cognition, and figural
creativity was positively associated with functional outcome.
Additionally, social cognition and figural creativity were positively
related to each other. On the other hand, negative symptoms
were negatively related to figural creativity. Finally, neurocogni-
tion was also directly and positively related to functional
outcomes. The fit of the model was also very good, SB χ2 (32, N
= 96) = 40.445, CFI= 0.954, NNFI= 0.936, and SRMR= 0.073.
Next, the significance of the mediational paths was examined via
5,000 bootstrapping samples. The results indicated that figural
creativity acted as mediating variable between neurocognition
and functional outcome (0.340; 95% confidence interval [0.332,
0.350]) and that figural creativity mediated between negative
symptoms and functional outcome (−0.020; 95% confidence
interval [−0.021, −0.020]).
In addition, an alternative model was tested in which figural
creativity mediated between neurocognition, social cognition, and
functional outcome. The Satorra-Bentler’s scaled chi-square
difference test48 showed that there were not statistically
significant differences between the two models [ΔSB χ2 difference
(1, N= 96) = 0.233, p= 0.629]. Although there were not
statistically significant differences and the fit indexes where very
similar, only the first model was included in the current study.
DISCUSSION
The aim of this study was to analyze the predictive value of
creativity on functional outcome through a mediational model
including sociodemographic, clinical, neurocognitive, social cog-
nitive, creativity, and functional outcome variables. To our
knowledge, this is the first study analyzing the mediatory role of
creativity on functional outcome of patients with schizophrenia.
As hypothesized, creativity was significantly associated with
functional outcome. More specifically, figural creativity acted as
mediator between neurocognition and functional outcome as well
as between negative symptoms and functional outcome. Addi-
tionally, neurocognition was directly associated with functional
outcome. Moreover, although social cognition was not directly
related to functional outcome, it was associated with figural
creativity and neurocognition. However, contrary to what was
expected based on previous literature1,6,10, negative symptoms
were not directly related to functional outcome and cognitive
functioning.
The association found between creativity and functional
outcome supports the idea that creative problem solving skills
are also applied to real-life problems27,30 and therefore, are crucial
for daily life functioning. Hence, our findings suggest that patients
with schizophrenia who have better creative skills may benefit
from this resource to better adapt and cope with their multiple
adversities in daily life functioning. As indicated by several
authors31,32, creativity can be an adaptive ability capable of
improving individuals’ both physical and psychological health. In
line with our results, few studies have suggested that creativity
could influence the functional outcome of individuals with
schizophrenia25, bipolar disorder31, and elderly people32.
As expected, creativity was related to neurocognition and social
cognition, and mediated the relationship between neurocognition
and functional outcome. The association between neurocognition
and social cognition with creativity is consistent with previous
research carried out in this pathology38–41. Similar to this study,
another capacity that is related to creativity43,44, metacognition
capacity, has also been shown to mediate the relationship
between neurocognition and functional outcome in
schizophrenia47.
With respect to the association between cognition and
functional outcome, in line with previous studies, neurocognition
was strongly associated with functional outcome6,9,17–19. However,
contrary to other studies1,23,24, this association was not mediated
by social cognition. In fact, neurocognition was found to be both
directly related to functional outcome and through figural
creativity. The reason for this may have been that in this study,
unexpectedly, social cognition was not directly associated with
functional outcome, which could have made the association
between neurocognition and functional outcome stronger. A large
Table 3. Correlations between clinical characteristics, neurocognition, social cognition, creativity, and functional outcome.
1 2 3 4 5 6 7 8 9 10 11 12
Duration of illness 1
Negative symptoms 0.087 1
Positive symptoms −0.042 0.045 1
Disorganization 0.101 0.223* 0.446** 1
Excited −0.068 0.052 0.482** 0.321** 1
Depressed −0.072 0.207* 0.304* 0.186 0.226* 1
Neurocognition −0.291* −0.175 −0.120 −0.244* −0.038 −0.105 1
Social cognition −0.197 −0.109 −0.001 −0.291* 0.028 0.024 0.527** 1
Figural creativity −0.001 −0.284* −0.107 −0.125 −0.081 0.049 0.233* 0.304* 1
Figural strengths −0.021 −0.160 0.021 −0.054 0.051 −0.145 0.245* 0.462** 0.581** 1
Verbal creativity −0.064 −0.237* −0.052 −0.067 −0.166 0.137 0.161 0.298* 0.288* 0.202 1
Functional outcome −0.059 −0.173 −0.017 −0.044 −0.058 −0.034 0.244* 0.063 0.270* 0.029 0.052 1
*p ≤ 0.05; **p ≤ 0.001.
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number of studies have shown a strong relationship between
social cognition and functional outcome1,21–24. Nevertheless, as in
this study, other studies have also found an association between
neurocognition and functional outcome, but not with social
cognition9,19. This may be due to the particular test employed for
the measurement of functional outcome. Being a reduced version
of the original scale, functional outcome may not have been
measured as comprehensively as in other studies1,23. Despite the
lack of significant results, social cognition should not be under-
estimated as it has been shown to be a relevant predictor of
functional outcome1,21–24.
Regarding clinical symptoms, negative symptoms were nega-
tively related to creativity, showing an indirect association with
functional outcome through the mediating role of creativity. Other
studies carried out on schizophrenia have also found an
association between negative symptoms and creativity39,41. This
makes sense, as some negative symptoms such as avolition can
make a creativity task particularly difficult. However, no clinical
symptoms were directly related to functional outcome, and only
disorganization was related to cognitive functioning. This was an
unexpected result, as in general, studies have found a positive
association between clinical symptoms and functional outcome in
schizophrenia; some of them only with negative symptoms6,12,
but others with both positive and negative symptoms1,10,11 or
with disorganization1. In contrast, very few studies have found
little or even no association between symptoms and functional
outcome49,50. Additionally, studies have found associations
between clinical symptoms and cognitive functioning1,6,12,13. In
line with this study, Galderisi et al.1 found an association between
disorganization and neurocognition, which makes sense since this
clinical variable is related to attentional capacity and abstract
thinking. The lack of significant results overall with clinical
symptoms in this study may be partly due to the different scales
or the different scoring methods used for the assessment of
clinical symptoms and functional outcome across studies. In fact,
some of the studies that have used the same scales as in this study
have employed a different scoring method1,11,13,51. For instance,
Bechi et al. used the Positive and Negative Syndrome Scale
(PANSS) to assess clinical symptoms, but employed a different
scoring method51. Galderisi et al.1 did use the same scoring
method for the positive symptoms and disorganization, but not
for the negative symptoms and they used different measures for
functional outcome.
Taken together, findings from this study support the well-
known idea that cognitive functioning contributes to functional
outcome in schizophrenia and point out the specific role of
creativity in this association. Additionally, these results also
support the association between negative symptoms and func-
tional outcome through creativity. As Richards stated, in the face
of adversity, humans have the potential for resilient creative
responses31. Thus, creativity seems to be a key capacity for the
performance of daily life activities and for dealing with real-life
challenging situations. These results mark an important milestone
and open a new window to future lines of research that could
explore other possible factors as determinants of functional
outcome in schizophrenia. Indeed, research should not only focus
on the negative aspects of the disease, such as clinical symptoms
or cognitive impairment, as possible predictors of functional
outcome, but there should be a shift towards positive psychology.
In fact, in addition to creative capacity, other resources such as
resilience or positive humor should be taken into account when
studying functional outcome. Regarding resilience, Galderisi et al.
already found that resilience has a relevant implication in real-life
functioning among patients with schizophrenia1. This capacity has
been closely related to creativity and has even been suggested
that creativity is a potential tool to promote resilience52. With
respect to humor, this has also been associated with creativity and
it is supposed to enhance creativity53. Cai et al. found that a
humor intervention had positive effects on different domains such
as negative symptoms, depression, and anxiety among patients
with schizophrenia, although they did not measure functional
outcome54. Furthermore, the involvement of these kinds of
resources on functional outcome should not be limited only to
the field of psychosis, but to the whole field of psychopathology
as well as to the healthy population.
The importance of this study lies in the fact that understanding
which factors underlie functional outcome is vital for the
development of more efficient treatment programs. Moreover,
2.73 (1.17)*
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Fig. 1 Model of mediation explaining functional outcome through negative symptoms, neurocognition, social cognition, and figural
creativity. Given values are non-standardized coefficients with standard errors in parentheses. *p ≤ 0.05; **p ≤ 0.001.
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the identification of mediators of functional outcome is essential,
since these, being closer to the outcome of interest, should
become the target of interventions16. Specifically, these results
provide further evidence for the idea that including training on
creative problem-solving skills could be beneficial for the
improvement of functional outcome in this disease37. Not only
in psychosis, but it is suggested that the training or practice of
positive resources such as creativity have a positive impact on
personal well-being and quality of life of the general popula-
tion55,56. Nevertheless, there are multiple ways of improving
creativity. For instance, it could be promoted through “creative-
training programs” that include problem-solving or divergent
thinking exercises37,55. Alternatively, it could be enhanced through
creative activities aimed at improving well-being, such as art
therapy55. Furthermore, creativity could also be trained indirectly
through other kind of interventions such as humor intervention or
laughter therapy53, through cognitive remediation57, or by means
of transcranial direct current and random noise stimulation58–60. In
addition, the inclusion of training of positive resources such as
creativity or humor in rehabilitation programs could encourage
adherence to treatment and motivation, since it may be more
interesting for patients. As noted by Cai et al., including training in
positive resources could facilitate coping abilities as well as social
functioning54. Altogether, evidence suggests that integrated
and holistic treatments addressing multiple domains such as
neurocognition, social cognition, and creativity as well as negative
symptoms should be applied in order to improve real-life
functioning in mental disorders. In fact, the use of combined
and multidisciplinary treatments could produce better results
than applying them individually, as they could be mutually
reinforcing.
Several limitations should be considered in this study. First,
functional outcome was addressed through a social functioning
scale which included the assessment of different dimensions of
real-world functioning (e.g., interpersonal relations, independent
living, and employment); however, the additional measurement
of other domains such as quality of life or a more exhaustive
assessment of some domains like vocational functioning would
have provided a broader picture of the impact of creativity on
functional outcome. Second, since this study aimed to explore
the role of creativity on daily functioning, creativity assessment
could have included the measure of everyday creativity in
addition to the creativity tasks employed. Future studies should
include this kind of scales to acquire a greater understanding
about its role in functional outcomes. Third, though this study
included a multidimensional neurocognitive evaluation, it would
be interesting for future research to analyze the role of other
additional cognitive domains also impaired in schizophrenia
such as visual and auditory perception or visual memory, in order
to provide a further understanding of the role of neurocognition
in creativity in this disease. Fourth, the sample was unbalanced
towards men, which may have affected the interpretation of the
results. Nevertheless, sex was entered in the mediational model
to control for its possible effect. Fifth, the small sample size
limited the statistical power of the mediational analysis and
prevented the inclusion of individual cognitive dimensions, thus
more studies should be conducted with larger samples and
findings from this study need to be interpreted with care. Finally,
the cross-sectional design of this study did not allow to test
causal relationships, so results from the present study should be
considered with caution. Future studies could analyze these
possible long-term relationships. Bearing these limitations in
mind, we believe that this study provides initial and relevant
evidence of the mediational role of creativity in daily life
functioning in schizophrenia, which has significant implications
on the development of interventions aimed at improving
functional outcomes. Furthermore, this study opens up a new
field of research on additional personal resources as possible




Ninety-six patients diagnosed with schizophrenia (85 males and 11
females) were recruited from the Psychiatric Hospital of Álava and the
Mental Health Network in Álava (Spain). All patients met the diagnostic
criteria for schizophrenia according to the Structured Clinical Interview for
DSM-V (the American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition)61. The mean age of the sample
was 41.37 (SD= 10.79) years old and mean years of education was 10.25
(SD= 2.56). 77.08% of the sample were right-handed, 4.16% left-handed,
and 18.75% mixed-handed. The 58.3% of the sample were outpatients and
41.7% were inpatients. Mean age of onset of the disease was 22.79 (SD=
5.67), with a mean of previous hospitalizations of 5.84 (SD= 6.31), mean
duration of illness of 18.59 (SD= 10.31), and a mean of medication dosage
(chlorpromazine equivalent doses - mg/day) of 511.37 (SD= 295.51). The
defined daily dose method was used to change medication to
chlorpromazine62,63.
Exclusion criteria consisted of: (a) clinical instability (meeting the relapse
criteria of Csernansky et al.64); (b) significant changes in the antipsychotic
treatment in the previous three months; (c) cognitive impairment
secondary to another disease; (d) diagnosis of an active Major Affective
Disorder; and (e) diagnosis of Substance Use Disorder (DSM-V)61 including
alcohol during the six months prior to study inclusion (with the exception
of nicotine). All participants took part voluntarily, providing written
informed consent to participate, and they did not receive any monetary
reward for taking part in the study. The study protocol was approved by
the Clinical Research Ethics Committees of the Autonomous Region of the
Basque Country (CEIC-E) in Spain (PI2017044). This study forms part of a
larger ongoing project, which is registered in clinicaltrials.gov
(NCT03509597).
Measures
Neurocognition. Neurocognition was measured by means of the follow-
ing tests assessing cognitive flexibility, processing speed, working memory,
verbal memory, and inhibition: the number of categories completed and
the number of perseverative errors from the Modified Wisconsin Card
Sorting Test (M-WCST)65; Word, Color, and Word-Color values from the
Stroop Color and Word Test66; the Backward Digit Span subtest from the
Wechsler Adult Intelligence Scale-III (WAIS-III)67; the three learning trials
and the delayed recall trial from the Hopkins Verbal Learning Test (HVLT
version 2)68; and the Symbol-Coding subtest from the Wechsler Adult
Intelligence Scale-III67. All these neurocognitive scores were converted into
Z-scores based on the sample of the study. Some scores were adjusted so
that higher scores indicated better cognitive performance. A neurocogni-
tion composite was then obtained using these Z-scores (Cronbach’s
alpha = 0.77).
Social cognition. The evaluation of social cognition included the
measurement of three domains: theory of mind, social perception, and
emotion processing. Theory of mind was assessed by means of the Happé
Test “Strange Stories Task”69. Four stories from this test were used. Social
perception was measured through the Social Attribution Task-Multiple
Choice II (SAT-MC-II)70. Finally, for the assessment of emotion processing,
the Spanish adaptation of the Bell Lysaker Emotion Recognition Test
(BLERT)71 was used. A composite score of social cognition was obtained
from the Z scores of these three tests based on the sample of the study
(Cronbach’s alpha = 0.70).
Creativity. Figural and verbal creativity were assessed by means of two
subtests from the Torrance Test of Creative Thinking72,73. Figural creativity
was measured through the Picture Completion subtest. This task consists of
completing ten unfinished pictures by producing as many ideas as
possible. The following dimensions were obtained: originality, fluency,
flexibility, elaboration, resistance to premature closure, and abstractness of
titles. Flexibility was scored using the criteria from the Spanish adaptation
of the Torrance Test of Creative Thinking74. Total figural creativity score
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was calculated through the sum of these six dimensions. In addition, a
figural creative strengths score was calculated based on the manual73.
Figural creative strengths consisted of 11 criterion-referenced measures:
emotional expressiveness, storytelling articulateness, movement or action,
expressiveness of titles, synthesis of incomplete figures, unusual visualiza-
tion, internal visualization, humor, richness of imagery, colorfulness of
imagery, and fantasy.
The Unusual Uses subtest was administered in order to assess verbal
creativity. In this activity, participants are asked to write as many unusual
uses as possible for cardboard boxes. Originality, fluency, and flexibility
dimensions were measured. The sum of these three dimensions was used
to obtain the total verbal creativity score. Four minutes were given to
complete each subtest.
Clinical symptoms. The PANSS75 was used for the assessment of positive
symptoms and general psychopathology. Scores for the dimensions
“positive symptoms”, “disorganization”, “excitement”, and “depression”
were obtained following the consensus 5-factor solution proposed by
Wallwork et al.76, which included four, three, four, and three items
respectively. As recommended by the NIMH-MATRICS Consensus State-
ment on Negative Symptoms77,78, negative symptoms were measured
through the Brief Negative Symptom Scale (BNSS)79, composed of
13 items.
Functional outcome. Functional outcome was measured using the short
Spanish version of the Social Functioning Scale (SFS)80. It consists of a 15-
item self-report scale that evaluates different functioning domains
including social engagement and withdrawal, interpersonal communica-
tion, pro-social activities, independence (competence and performance),
recreation, and employment.
Handedness. Handedness was measured through the Edinburgh Hand-
edness Inventory81. The formula (right - left/right + left) was used to
calculate handedness consistency and the scores obtained ranged from
100 (wholly right-handed) to −100 (wholly left-handed). Participants who
obtained scores ranging from −79 to 79 were considered to be mixed-
handed, and those with scores ranging from −100 to −80 or from 80 to
100 to be consistent-handed.
An expert neuropsychologist administered and corrected all the
cognitive and creativity tests and clinical symptoms were assessed by
expert trained psychiatrists.
Data analyses
Statistical analyses were carried out by IBM SPSS version 26.0 (SPSS Inc.,
Chicago, USA). Data were tested for normality using the Kolmogorov-
Smirnov test. Missing values were imputed using the expectation
maximization (EM) algorithm. Spearman´s Rho, Pearson’s r and point-
biserial correlations were performed between sociodemographic, clinical,
neurocognitive, social cognitive, creative, and functional outcome
variables. Significance level was set at 0.05.
To test the mediation hypothesis, path analysis was used with LISREL
9.282. The robust maximum likelihood (RML) method was employed,
which requires an estimate of the asymptotic covariance matrix of the
variances and covariates of the sample and includes the scaled χ2
Satorra-Bentler index (SB χ2). The goodness of fit of the model was
evaluated by CFI, NNFI, and SRMR. According to Hu and Bentler83, CFI and
NNFI values higher than .90, and SRMR values smaller than .08 reflect a
good fit83. The Satorra-Bentler’s scaled chi-square difference test48 was
performed to compare two alternative models, using the specific
program designed by Crawford and Henry84.
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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